natgillin/translations-raw huggingface dataset:
This is because Azacitidine Celgene may affect the way some other medicines work. 
Zdravilo Azacitidine Celgene lahko vpliva na način delovanja nekaterih drugih zdravil.
Area under the curve and maximum plasma concentration (Cmax) of subcutaneous admiminstration of azacitidine were approximately proportional within the 25 to 100 mg/m dose range. 
Površina pod krivuljo in najvišja koncentracija v plazmi (Cmax) pri subkutanem dajanju azacitidina sta bili v razponu odmerkov 25 do 100 mg/m približno proporcionalni.
Before giving you Azacitidine Celgene, your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle. 
Preden vam bo zdravnik predpisal zdravilo Azacitidine Celgene, vam bo predpisal druga zdravila za preprečevanje slabosti in bruhanja na začetku vsakega cikla,.
9/L), baseline bone marrow blasts (≤ 50% & > 50%) and prior history of MDS] there was a trend in OS benefit in favour of azacitidine. 
9/l), izhodiščnimi blastnimi celicami v kostnem mozgu (≤ 50 % & > 50 %) in prejšnjo anamnezo MDS] se je pokazala tendenca v korist celokupnemu preživetju (OS) v prid azacitidinu.
The efficacy and safety of azacitidine was studied in an international, multicentre, controlled, openlabel, parallel group Phase 3 study in patients 65 years and older with newly diagnosed de novo or secondary AML with >30% bone marrow blasts according to the WHO classification, who were not eligible for HSCT. 
Učinkovitost in varnost azacitidina so proučevali v mednarodni, multicentrični, kontrolirani, odprti študiji 3. faze s paralelnimi skupinami pri bolnikih, starih 65 let ali več, z novo diagnosticirano de novo ali sekundarno AML z >30 % blastnih celic v kostnem mozgu po klasifikaciji SZO, ki niso bili primerni za PKMC.
What Azacitidine Celgene is and what it is used for What you need to know before you use Azacitidine Celgene How to use Azacitidine Celgene Possible side effects 
Kaj je zdravilo Azacitidine Celgene in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Azacitidine Celgene Kako uporabljati zdravilo Azacitidin Celgene Možni neželeni učinki
Following subcutaneous administration of a single 75 mg/m dose, mean exposure values (AUC and Cmax) from subjects with mild, moderate and severe renal impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal function subjects. 
Po subkutanem dajanju enkratnega odmerka 75 mg/m so se srednje vrednosti izpostavljenosti (AUC in Cmax) oseb z blago, zmerno in hudo okvaro ledvic zvečale za 11-21 %, 15-27 % oziroma 41-66 % v primerjavi z osebami z normalno ledvično funkcijo.
The absolute bioavailability of azacitidine after subcutaneous relative to intravenous administration (single 75 mg/m doses) was approximately 89% based on area under the curve (AUC). 
Absolutna biološka razpoložljivost azacitidina, danega subkutano, v primerjavi z intravensko danim azacitidinom (enkratni odmerki po 75 mg/m2) je bila približno 89 %, na osnovi površine pod krivuljo (AUC - area under the curve).
What you need to know before you use Azacitidine Celgene 
Kaj morate vedeti, preden boste uporabili zdravilo Azacitidine Celgene
Adult population with MDS, CMML and AML (20-30% marrow blasts) Adverse reactions considered to be possibly or probably related to the administration of azacitidine have occurred in 97 % of patients. 
Odrasla populacija z MDS, CMML in AML (20-30 % blastnih celic v kostnem mozgu) Neželeni učinki, ki so morda ali verjetno povezani z zdravljenjem z azacitidinom, so se pojavili pri 97 % bolnikov.
• Low levels of potassium in your blood. 
• nizka raven kalija v krvi
The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m of body surface area, injected subcutaneously, daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle). 
Priporočen začetni odmerek za prvi cikel zdravljenja je za vse bolnike, ne glede na izhodiščne hematološke laboratorijske vrednosti, 75 mg/m površine telesa, injicirano subkutano enkrat dnevno 7 dni, ki jim sledi 21-dnevno obdobje mirovanja (28-dnevni cikel zdravljenja).
Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) ≥ 3.0 x 10 
število levkocitov (WBC - White Blood Cells) ≥ 3,0 x 10
Adult population (MDS, CMML and AML [20-30% marrow blasts]) The efficacy and safety of azacitidine were studied in an international, multicenter, controlled, openlabel, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system. 
Odrasla populacija (MDS, CMML in AML [20-30 % blastnih celic v kostnem mozgu]) Učinkovitost in varnost azacitidina sta bili preučeni v mednarodni, multicentrični, kontrolirani, odprti, randomizirani primerjalni študiji 3. faze z vzporednimi skupinami (AZA PH GL 2003 CL 001) pri odraslih bolnikih z: MDS z vmesno stopnjo 2 in visoko stopnjo tveganja po Mednarodnem prognostičnem sistemu ocenjevanja (IPSS - International Prognostic Scoring System), refraktorno anemijo s presežkom blastov (RAEB - refractory anaemia with excess blasts), refraktorno anemijo s presežkom blastov v transformaciji (RAEB-T - refractory anaemia with excess blastsin transformation) in modificirano kronično mielomonocitno levkemijo (mKMMoL) po francosko-ameriško-britanskem (FAB - French American British) razvrstitvenem sistemu.
Adult population aged 65 years or older with AML with > 30% marrow blasts The results presented below represent the intent-to-treat population studied in AZA-AML-001 (see section 4.1 for the approved indication). 
Odrasla populacija, stara 65 let ali več, z AML z > 30 % blastnih celic v kostnem mozgu Rezultati, predstavljeni v nadaljevanju, predstavljajo populacijo, namenjeno za zdravljenje, ki so jo proučili v študiji AZA-AML-001 (glejte poglavje 4.1 za odobreno indikacijo).
Absorption Following subcutaneous administration of a single 75 mg/m dose, azacitidine was rapidly absorbed with peak plasma concentrations of 750 ± 403 ng/mL occurring at 0.5 h after dosing (the first sampling point). 
Absorpcija Po subkutanem dajanju enkratnega odmerka 75 mg/m se je azacitidin hitro absorbiral z najvišjimi koncentracijami v plazmi 750 ± 403 ng/ml, ki so se pojavile 0,5 ure po injiciranju (prva točka vzorčenja).
• acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, 
• akutno mieloično levkemijo (AML) z 20-30 % blastnih celic in displazijo več celičnih linij po razvrstitvi Svetovne zdravstvene organizacije (SZO),
Reconstituted Azacitidine Celgene should be injected subcutaneously (insert the needle at a 45-90° angle) using a 25-gauge needle into the upper arm, thigh or abdomen. 
Rekonstituirano zdravilo Azacitidine Celgene injicirajte subkutano (iglo vstavite pod kotom 45-90°) z iglo velikosti 25 G v nadlaket, stegno ali trebuh.
Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets ≤ 50.0 x 10 
Prilagoditev odmerka zaradi hematološke toksičnosti Hematološka toksičnost je opredeljena kot najnižje število celic v enem ciklu (najnižja točka), če je število trombocitov ≤ 50,0 x 10
Adult population aged 65 years or older with AML with > 30% marrow blasts The most common serious adverse reactions (≥ 10%) noted from AZA-AML-001 within the azacitidine treatment arm included febrile neutropenia (25.0%), pneumonia (20.3%), and pyrexia (10.6%). 
Odrasla populacija, stara 65 let ali več, z AML z > 30 % blastnih celic v kostnem mozgu Najpogostejši resni neželeni učinki (≥ 10 %), ki so jih opazili v študiji AZA-AML-001 v skupini zdravljenja z azacitidinom, so vključevali febrilno nevtropenijo (25,0 %), pljučnico (20,3 %) in pireksijo (10,6 %).
If haematological toxicity is observed following Azacitidine Celgene treatment, the next cycle of the therapy should be delayed until the platelet count and the ANC have recovered. 
Če se po zdravljenju z zdravilom Azacitidine Celgene opazi hematološka toksičnost, je treba naslednji cikel zdravljenja prestaviti do obnovitve števila trombocitov in ANC.
What Azacitidine Celgene is and what it is used for 
Kaj je zdravilo Azacitidine Celgene in za kaj ga uporabljamo
What Azacitidine Celgene looks like and contents of the pack Azacitidine Celgene is a white powder for suspension for injection and is supplied in a glass vial containing 100 mg of azacitidine. 
Izgled zdravila Azacitidine Celgene in vsebina pakiranja Zdravilo Azacitidine Celgene je bel prašek za suspenzijo za injiciranje, ki je na voljo v stekleni viali, ki vsebuje 100 mg azacitidina.
Men should not father a child while receiving treatment with Azacitidine Celgene. 
Moški naj med zdravljenjem z zdravilom Azacitidine Celgene ne zaplodijo otroka.
Azacitidine treatment was associated with a median time to death or transformation to AML of 13.0 months versus 7.6 months for those receiving CCR treatment, an improvement of 5.4 months with a stratified log-rank p-value of 0.0025. 
Zdravljenje z azacitidinom je bilo povezano z mediano časa do smrti ali pretvorbo v AML 13,0 mesecev v primerjavi s 7,6 meseci za bolnike, zdravljene s CCR, kar predstavlja izboljšanje za 5,4 mesece s stratificirano log-rank p-vrednostjo 0,0025.
Azacitidine Celgene works by preventing cancer cells from growing. 
Zdravilo Azacitidine Celgene deluje tako, da rakastim celicam preprečuje rast.
9/l or ANC < 1.5 x 10 
9/l ali ANC < 1,5 x 10
Total dose (mg) = Dose (mg/m 2) x BSA (m 
Celotni odmerek glede na površino telesa (BSA - body surface area) se izračuna tako: Celotni odmerek (mg) = odmerek (mg/m2) x BSA (m
Azacitidine Celgene therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated. 
Pri bolnikih, pri katerih se razvije nekrotizantni fasciitis, je treba zdravljenje z zdravilom Azacitidine Celgene prekiniti in takoj začeti ustrezno zdravljenje.
If the decrease in WBC or ANC or platelets is greater than 50 % from that prior to treatment, with no improvement in cell line differentiation, the next cycle of Azacitidine Celgene therapy should be delayed until the platelet count and the ANC have recovered. 
Če je zmanjšanje števila levkocitov ali ANC ali trombocitov večje od 50 % od stanja pred zdravljenjem in ni izboljšanja v diferenciaciji celične linije, je treba naslednji cikel zdravljenja z zdravilom Azacitidine Celgene prestaviti do obnovitve števila trombocitov in ANC.
Azacitidine Celgene contains the active substance ‘azacitidine'. 
Zdravilo Azacitidine Celgene vsebuje zdravilno učinkovino 'azacitidin'.
In the ITT analysis of 488 patients (241 azacitidine and 247 CCR), azacitidine treatment was associated with a median survival of 10.4 months versus 6.5 months for those receiving CCR treatment, a difference of 3.8 months, with a stratified log-rank p-value of 0.1009 (two- sided). 
V analizi ITT 488 bolnikov (241 azacitidin in 247 CCR) je bilo zdravljenje z azacitidinom povezano z medianim preživetjem 10,4 meseca proti 6,5 meseca pri tistih, ki so prejemali zdravljenje CCR, kar je razlika 3,8 meseca, s stratificirano log-rank vrednostjo p 0,1009 (dvostransko).
Azacitidine was administered at a subcutaneous dose of 75 mg/m daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle) for a median of 9 cycles (range = 1-39) and a mean of 10.2 cycles. 
Bolniki so azacitidin prejemali kot subkutani odmerek 75 mg/m dnevno 7 dni, ki jim je sledilo 21-dnevno obdobje mirovanja (28-dnevni cikel zdravljenja), z mediano 9 ciklov (razpon = 1-39) in povprečjem 10,2 ciklov.
You will have blood tests before you begin treatment with Azacitidine Celgene and at the start of each period of treatment (called a ‘cycle'). 
Pred začetkom zdravljenja z zdravilom Azacitidine Celgene in ob začetku vsakega obdobja zdravljenja (imenovanega ‘cikel') boste opravili preglede krvi.
Azacitidine Celgene is a cytotoxic medicinal product and, as with other potentially toxic compounds, caution should be exercised when handling and preparing azacitidine suspensions. 
Zdravilo Azacitidine Celgene je citotoksično zdravilo, zato je pri rokovanju s suspenzijo azacitidina in njeno pripravo potrebna previdnost, kot pri drugih potencialno toksičnih sestavinah.
Azacitidine treatment improved peripheral blood counts and led to a reduced need for RBC and platelet transfusions. 
Zdravljenje z azacitidinom je izboljšalo periferno krvno sliko in zmanjšalo potrebo po transfuzijah eritrocitov in trombocitov.
Patients received the pre-selected regimen if not randomised to azacitidine. 
Bolniki so prejemali vnaprej izbrano shemo zdravljenja, če niso bili naključno razvrščeni na azacitidin.
Overall response rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) as determined by the IRC was 27.8% in the azacitidine group and 25.1% in the combined CCR group (p = 0.5384). 
Stopnja celokupnega odziva (popolna remisija [CR] + popolna remisija z nepopolnim okrevanjem krvne slike [CRi]), ki jo je ugotovil IRC, je bila v skupini z azacitidinom 27,8 %, v skupini s kombiniranim CCR pa 25,1 % (p = 0,5384).
Azacitidine Celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: 
Zdravilo Azacitidine Celgene je indicirano za zdravljenje odraslih bolnikov, ki niso primerni za presaditev krvotvornih matičnih celic (PKMC) s/z:
In the ITT analysis of 358 patients (179 azacitidine and 179 CCR), azacitidine treatment was associated with a median survival of 24.46 months versus 15.02 months for those receiving CCR treatment, a difference of 9.4 months, with a stratified log-rank p-value of 0.0001. 
V analizi skupine 358 bolnikov ITT (179 azacitidin in 179 CCR), je bilo zdravljenje z azacitidinom povezano z mediano preživetja 24,46 mesecev v primerjavi s 15,02 meseca v skupini, zdravljeni s CCR, kar predstavlja 9,4 mesecev razlike, s stratificirano log-rank p-vrednostjo 0,0001.
When Azacitidine Celgene is reconstituted using water for injections that has not been refrigerated, chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 25 °C for 45 minutes and at 2 °C to 8 °C for 8 hours. 
Pri rekonstituciji zdravila Azacitidine Celgene z vodo za injekcije, ki ni bila v hladilniku, je rekonstituirano zdravilo kemijsko in fizikalno stabilno 45 minut pri 25 °C in 8 ur pri 2 °C do 8 °C.
In patients who achieved CR or CRi, the median duration of remission was 10.4 months (95% CI = 7.2, 15.2) for the azacitidine subjects and 12.3 months (95% CI = 9.0, 17.0) for the CCR subjects. 
Pri bolnikih, ki so dosegli CR ali CRi, je bilo mediano trajanje remisije 10,4 meseca (95 % IZ = 7,2; 15,2) pri preskušancih z azacitidinom in 12,3 meseca (95 % IZ = 9,0; 17,0) pri preskušancih s CCR.
CCR consisted of BSC alone (n=45), low-dose cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and anthracycline plus BSC (n=44). 
CCR so sestavljali samo BSC (n=45), citarabin v majhnem odmerku skupaj z BSC (n=158) ali standardna intenzivna kemoterapija s citarabinom in antraciklinom skupaj z BSC (n=44).
No accumulation occurs after subcutaneous administration of 75 mg/m azacitidine once daily for 7 days. 
Po 7-dnevnem subkutanem dajanju 75 mg/m azacitidina enkrat na dan ne pride do kopičenja.
21 days (28 day treatment cycle), for a median of 6 cycles (range: 1 to 28), BSC- only patients for a median of 3 cycles (range: 1 to 20), low-dose cytarabine patients for a median of 4 cycles (range 1 to 25) and standard intensive chemotherapy patients for a median of 2 cycles (range: 1 to 3, induction cycle plus 1 or 2 consolidation cycles). 
Azacitidin so dajali v s.c. odmerku 75 mg/m2/dan 7 dni, sledilo je obdobje mirovanja, ki je trajalo 21 dni (28-dnevni cikel zdravljenja), mediana števila ciklov je bila 6 (razpon: 1 do 28), pri bolnikih, ki so prejemali samo BSC, je bila mediana števila ciklov 3 (razpon: 1 do 20), pri bolnikih, ki so prejemali citarabin v majhnem odmerku, je bila mediana števila ciklov 4 (razpon 1 do 25), pri bolnikih, ki so prejemali standardno intenzivno kemoterapijo, pa je bila mediana števila ciklov 2 (razpon: 1 do 3, indukcijski cikel plus 1 ali 2 konsolidacijska cikla).
Each pack contains one vial of Azacitidine Celgene. 
Ena škatla vsebuje eno vialo zdravila Azacitidine Celgene.
Following intravenous and subcutaneous administration of C-azacitidine, 85 and 50 % of the administered radioactivity was recovered in urine respectively, while < 1 % was recovered in faeces. 
C-azacitidina so zaznali 85 % oziroma 50 % radioaktivnosti v urinu in le < 1 % v blatu.
In all pre- specified subgroups age [(< 75 years & ≥ 75 years), gender, race, ECOG performance status (0 or 1 & 2) , baseline cytogenetic risk (intermediate & poor) , geographic region, WHO classification of AML (including AML with myelodysplasia-related changes), baseline WBC count (≤ 5 x10 
V vseh vnaprej določenih podskupinah po starosti[(< 75 let & ≥ 75 let), spolu, rasi, stanju zmogljivosti po ECOG (0 ali 1 & 2), izhodiščnem citogenetskem tveganju (srednje & veliko), zemljepisnem območju, razvrstitvi AML po klasifikaciji SZO (vključno z AML s spremembami, povezanimi z mielodisplazijo), izhodiščnim številom belih krvničk (≤ 5 x10
The survival benefits of azacitidine were consistent regardless of the CCR treatment option (BSC alone, low-dose cytarabine plus BSC or standard induction chemotherapy plus BSC) utilised in the control arm. 
Izboljšanje preživetja z azacitidinom je bilo dosledno, ne glede na izbrano skupino CCR (samo BSC, nizek odmerek citarabina plus BSC ali standardna indukcijska kemoterapija plus BSC) v kontrolni skupini.
Azacitidine Celgene 25 mg/mL powder for suspension for injection 
Azacitidine Celgene 25 mg/ml prašek za suspenzijo za injiciranje
2 D bar code carrying the unique identifier 
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
Do not use Azacitidine Celgene 
Ne uporabljajte zdravila Azacitidine Celgene
9/l, and platelets ≥ 75.0 x 10 
9/l in trombocitov ≥ 75,0 x 10
Vial(s) of azacitidine; vial(s) of water for injections; non-sterile surgical gloves; alcohol wipes; 5 mL injection syringe(s) with needle(s). 
vialo (viale) azacitidina; vialo (viale) vode za injekcije; nesterilne kirurške rokavice; alkoholne robčke; 5 ml injekcijsko brizgo (brizge) z iglo (iglami).
9/l and/or absolute neutrophil count (ANC) ≤ 1 x 10 
9/l in/ali je absolutno število nevtrofilcev (ANC - Absolute Neutrophil
A patient was considered RBC or platelet transfusion independent during the treatment period if the subject had no RBC or platelet transfusions during any consecutive 56 days during the reporting period, respectively. 
Verjetnost preživetja med obdobjem zdravljenja, če ni imel nobene transfuzije eritrocitov oziroma trombocitov v obdobju katerih koli zaporednih 56 dni med obdobjem poročanja.
Azacitidine Celgene is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4). 
Zdravilo Azacitidine Celgene je kontraindicirano pri bolnikih z napredovalo obliko malignih jetrnih tumorjev (glejte poglavji 4.3 in 4.4).
Azacitidine Celgene 25 mg/mL powder for suspension for injection Azacitidine 
Azacitidine Celgene 25 mg/ml prašek za suspenzijo za injiciranje azacitidin
Reconstituted Azacitidine Celgene should be injected subcutaneously into the upper arm, thigh or abdomen. 
Rekonstituirano zdravilo Azacitidine Celgene je treba injicirati pod kožo v nadlaket, stegno ali trebuh.
• Sore or runny nose or sinuses (sinusitis). 
• vnetje nosu, izcedek iz nosu ali sinuzitis
Your doctor, pharmacist or nurse are responsible for storing Azacitidine Celgene. 
Za shranjevanje zdravila Azacitidine Celgene je odgovoren vaš zdravnik, farmacevt ali medicinska sestra.
Azacitidine Celgene is used in adults who are not able to have a stem cell transplantation to treat: 
Za kaj zdravilo Azacitidin Celgene uporabljamo Zdravilo Azacitidine Celgene se uporablja pri odraslih bolnikih, pri katerih ni možna presaditev matičnih celic, za zdravljenje:
In patients who were platelet transfusion dependent at baseline and achieved transfusion independence on treatment, the median duration of platelet transfusion independence was 10.8 months in the azacitidine group and 19.2 months in the CCR group. 
Pri bolnikih, ki so bili v izhodišču odvisni od transfuzij trombocitov in so ob zdravljenju dosegli neodvisnost od transfuzij, je bilo mediano trajanje neodvisnosti od transfuzij trombocitov v skupini z azacitidinom 10,8 meseca, v skupini s CCR pa 19,2 meseca.
Of the patients in the azacitidine group who were platelet transfusion dependent at baseline, 40.6% (95% CI = 30.9, 50.8) of these patients became platelet transfusion independent during the treatment period, compared with 29.3% of (95% CI = 19.7, 40.4) patients in the combined CCR groups. 
Od bolnikov v skupini z azacitidinom, ki so bili v izhodišču odvisni od transfuzij trombocitov, jih je 40,6 % (95 % IZ = 30,9; 50,8) v obdobju zdravljenja postalo neodvisnih od transfuzij trombocitov, v primerjavi z 29,3 % (95 % IZ = 19,7; 40,4) bolnikov v skupinah s kombiniranimi CCR.
In patients who were RBC transfusion dependent at baseline and achieved transfusion independence on treatment, the median duration of RBC transfusion independence was 13.9 months in the azacitidine group and was not reached in the CCR group. 
Pri bolnikih, ki so bili v izhodišču odvisni od transfuzij eritrocitov in so ob zdravljenju dosegli neodvisnost od transfuzij, je bilo mediano trajanje neodvisnosti od transfuzij eritrocitov v skupini z azacitidinom 13,9 meseca, v skupini s CCR pa neodvisnosti niso dosegli.
How to use Azacitidine Celgene 
Kako uporabljati zdravilo Azacitidine Celgene
Method of administration Do not filter the suspension after reconstitution. 
Način uporabe Rekonstituirane suspenzije ne filtrirajte.
Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 38.5% (95% CI = 31.1, 46.2) of these patients became RBC transfusion independent during the treatment period, compared with 27.6% of (95% CI = 20.9, 35.1) patients in the combined CCR groups. 
Od bolnikov v skupini z azacitidinom, ki so bili v izhodišču odvisni od transfuzij eritrocitov, jih je 38,5 % (95 % IZ = 31,1; 46,2) v obdobju zdravljenja postalo neodvisnih od transfuzij eritrocitov, v primerjavi s 27,6 % (95 % IZ = 20,9; 35,1) bolnikov v skupinah s kombiniranimi CCR.
Following Azacitidine Celgene treatment, if the decrease in WBC or ANC or platelets from that prior to treatment is ≤ 50 %, or greater than 50 % but with an improvement in any cell line differentiation, the next cycle should not be delayed and no dose adjustment made. 
Po zdravljenju z zdravilom Azacitidine Celgene naslednjega cikla ni treba prestaviti in prilagajati odmerka, če je zmanjšanje števila levkocitov ali ANC ali trombocitov ≤ 50 % od stanja pred zdravljenjem ali večje kot 50 % z izboljšanjem v diferenciaciji katerekoli celične linije.
When Azacitidine Celgene is reconstituted using refrigerated (2 °C to 8 °C) water for injections, the chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 2 °C to 8 °C for 22 hours. 
Pri rekonstituciji zdravila Azacitidine Celgene z vodo za injekcije, ki je bila v hladilniku (2 °C do 8 °C), je rekonstituirano zdravilo kemijsko in fizikalno stabilno 22 ur pri 2 °C do 8 °C.
White lyophilised powder. 
Prašek za suspenzijo za injiciranje Bel liofiliziran prašek.
Read the leaflet for the shelf life of the reconstituted medicine. 
Za rok uporabnosti rekonstituiranega zdravila preberite priloženo navodilo.
*Recovery = counts ≥ nadir count + (0.5 x [baseline count - nadir count]) Patients with reduced baseline blood counts (i.e. WBC < 3.0 x 10 
*Obnovitev = število ≥ število v najnižji točki + (0,5 x [izhodiščno število - število v najnižji točki]) Bolniki, pri katerih je pred prvim zdravljenjem zmanjšano izhodiščno število krvnih celic (t.j.